Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma

Bevin Zimmerman, Aaron Sargeant, Kristina Landes, Soledad A. Fernandez, Ching Shih Chen, Michael Dale Lairmore

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) causes a variety of forms of adult T-cell leukemia/lymphoma (ATL), a refractory CD4+/CD25+ T-cell malignancy. Novel approaches to treat ATL patients are required due to the resistance of ATL to conventional chemotherapies. Histone deacetylase inhibitors (HDACi), which induce histone hyperacetylation leading to chromatin remodeling and reactivation of transcriptionally repressed genes have shown efficacy against a variety of cancers. Herein, we tested if valproic acid and the novel orally bioavailable HDACi, AR-42 reduced the proliferation of ATL cell lines by promoting apoptosis and histone hyperacetylation. Both compounds were cytotoxic and elicited a dose dependent increase in cytochrome C and cleaved Poly (ADP-ribose) polymerase (PARP) indicating the induction of cell death by apoptosis and promoted acetylation of histone H3 in both MT-2 and C8166 cell lines. We then evaluated the effects of AR-42, for survival in an ATL NOD/SCID mouse model. A dietary formulation of AR-42 prolonged survival of ATL engrafted mice compared to controls. Our data provide new directions for the treatment of ATL and support the further development of AR-42 against HTLV-1-associated lymphoid malignancies.

Original languageEnglish (US)
Pages (from-to)1491-1497
Number of pages7
JournalLeukemia Research
Volume35
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
Histone Deacetylase Inhibitors
T-Cell Lymphoma
Histones
Apoptosis
Formulated Food
Cell Line
Neoplasms
Inbred NOD Mouse
Chromatin Assembly and Disassembly
SCID Mice
Survival
Poly(ADP-ribose) Polymerases
Valproic Acid
Cytochromes
Acetylation
Cell Death
T-Lymphocytes
Drug Therapy

Keywords

  • Adult T-cell leukemia/lymphoma
  • Apoptosis
  • Histone deacetylase inhibitors (HDACi)
  • Human T-lymphotropic virus type 1 (HTLV-1)
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. / Zimmerman, Bevin; Sargeant, Aaron; Landes, Kristina; Fernandez, Soledad A.; Chen, Ching Shih; Lairmore, Michael Dale.

In: Leukemia Research, Vol. 35, No. 11, 11.2011, p. 1491-1497.

Research output: Contribution to journalArticle

Zimmerman, Bevin ; Sargeant, Aaron ; Landes, Kristina ; Fernandez, Soledad A. ; Chen, Ching Shih ; Lairmore, Michael Dale. / Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. In: Leukemia Research. 2011 ; Vol. 35, No. 11. pp. 1491-1497.
@article{3e27ec8bcc464683af9d3e048724c7c6,
title = "Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma",
abstract = "Human T-lymphotropic virus type 1 (HTLV-1) causes a variety of forms of adult T-cell leukemia/lymphoma (ATL), a refractory CD4+/CD25+ T-cell malignancy. Novel approaches to treat ATL patients are required due to the resistance of ATL to conventional chemotherapies. Histone deacetylase inhibitors (HDACi), which induce histone hyperacetylation leading to chromatin remodeling and reactivation of transcriptionally repressed genes have shown efficacy against a variety of cancers. Herein, we tested if valproic acid and the novel orally bioavailable HDACi, AR-42 reduced the proliferation of ATL cell lines by promoting apoptosis and histone hyperacetylation. Both compounds were cytotoxic and elicited a dose dependent increase in cytochrome C and cleaved Poly (ADP-ribose) polymerase (PARP) indicating the induction of cell death by apoptosis and promoted acetylation of histone H3 in both MT-2 and C8166 cell lines. We then evaluated the effects of AR-42, for survival in an ATL NOD/SCID mouse model. A dietary formulation of AR-42 prolonged survival of ATL engrafted mice compared to controls. Our data provide new directions for the treatment of ATL and support the further development of AR-42 against HTLV-1-associated lymphoid malignancies.",
keywords = "Adult T-cell leukemia/lymphoma, Apoptosis, Histone deacetylase inhibitors (HDACi), Human T-lymphotropic virus type 1 (HTLV-1), Therapy",
author = "Bevin Zimmerman and Aaron Sargeant and Kristina Landes and Fernandez, {Soledad A.} and Chen, {Ching Shih} and Lairmore, {Michael Dale}",
year = "2011",
month = "11",
doi = "10.1016/j.leukres.2011.07.015",
language = "English (US)",
volume = "35",
pages = "1491--1497",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma

AU - Zimmerman, Bevin

AU - Sargeant, Aaron

AU - Landes, Kristina

AU - Fernandez, Soledad A.

AU - Chen, Ching Shih

AU - Lairmore, Michael Dale

PY - 2011/11

Y1 - 2011/11

N2 - Human T-lymphotropic virus type 1 (HTLV-1) causes a variety of forms of adult T-cell leukemia/lymphoma (ATL), a refractory CD4+/CD25+ T-cell malignancy. Novel approaches to treat ATL patients are required due to the resistance of ATL to conventional chemotherapies. Histone deacetylase inhibitors (HDACi), which induce histone hyperacetylation leading to chromatin remodeling and reactivation of transcriptionally repressed genes have shown efficacy against a variety of cancers. Herein, we tested if valproic acid and the novel orally bioavailable HDACi, AR-42 reduced the proliferation of ATL cell lines by promoting apoptosis and histone hyperacetylation. Both compounds were cytotoxic and elicited a dose dependent increase in cytochrome C and cleaved Poly (ADP-ribose) polymerase (PARP) indicating the induction of cell death by apoptosis and promoted acetylation of histone H3 in both MT-2 and C8166 cell lines. We then evaluated the effects of AR-42, for survival in an ATL NOD/SCID mouse model. A dietary formulation of AR-42 prolonged survival of ATL engrafted mice compared to controls. Our data provide new directions for the treatment of ATL and support the further development of AR-42 against HTLV-1-associated lymphoid malignancies.

AB - Human T-lymphotropic virus type 1 (HTLV-1) causes a variety of forms of adult T-cell leukemia/lymphoma (ATL), a refractory CD4+/CD25+ T-cell malignancy. Novel approaches to treat ATL patients are required due to the resistance of ATL to conventional chemotherapies. Histone deacetylase inhibitors (HDACi), which induce histone hyperacetylation leading to chromatin remodeling and reactivation of transcriptionally repressed genes have shown efficacy against a variety of cancers. Herein, we tested if valproic acid and the novel orally bioavailable HDACi, AR-42 reduced the proliferation of ATL cell lines by promoting apoptosis and histone hyperacetylation. Both compounds were cytotoxic and elicited a dose dependent increase in cytochrome C and cleaved Poly (ADP-ribose) polymerase (PARP) indicating the induction of cell death by apoptosis and promoted acetylation of histone H3 in both MT-2 and C8166 cell lines. We then evaluated the effects of AR-42, for survival in an ATL NOD/SCID mouse model. A dietary formulation of AR-42 prolonged survival of ATL engrafted mice compared to controls. Our data provide new directions for the treatment of ATL and support the further development of AR-42 against HTLV-1-associated lymphoid malignancies.

KW - Adult T-cell leukemia/lymphoma

KW - Apoptosis

KW - Histone deacetylase inhibitors (HDACi)

KW - Human T-lymphotropic virus type 1 (HTLV-1)

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=80053969986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053969986&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.07.015

DO - 10.1016/j.leukres.2011.07.015

M3 - Article

VL - 35

SP - 1491

EP - 1497

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -